India’s growing heart valve disease burden and rising longevity are driving greater interest in structural heart therapies, but access, affordability, reimbursement and clinical capabilities remain key barriers to wider adoption of TAVI. Amit Raheja and Parameswaran Nair from Edward Lifesciences said TAVI volumes are growing rapidly, while the next phase of adoption will depend on stronger diagnosis and referral pathways, wider government-hospital access, heart-team capabilities and expansion of specialised care into tier-II cities.
News
TAVI Adoption Grows in India, but Access and Reimbursement Remain Key Hurdles
September 7, 2026India’s growing heart valve disease burden and rising longevity are driving greater interest in structural heart therapies, but access, affordability, reimbursement and clinical capabilities remain key barriers to wider adoption of TAVI. Amit Raheja and Parameswaran Nair from Edward Lifesciences said TAVI volumes are growing rapidly, while the next phase of adoption will depend on stronger diagnosis and referral pathways, wider government-hospital access, heart-team capabilities and expansion of specialised care into tier-II cities.